stoxline Quote Chart Rank Option Currency Glossary
  
Anika Therapeutics, Inc. (ANIK)
25.99  -0.29 (-1.1%)    06-17 16:00
Open: 26.15
High: 26.34
Volume: 34,781
  
Pre. Close: 26.28
Low: 25.88
Market Cap: 386(M)
Technical analysis
2024-06-17 5:21:28 PM
Short term     
Mid term     
Targets 6-month :  31.57 1-year :  36.87
Resists First :  27.03 Second :  31.57
Pivot price 25.94
Supports First :  25.1 Second :  23.91
MAs MA(5) :  26.04 MA(20) :  25.76
MA(100) :  25.41 MA(250) :  22.89
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  69.4 D(3) :  68.7
RSI RSI(14): 50.7
52-week High :  28.67 Low :  16.54
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ANIK ] has closed below upper band by 47.7%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 26.38 - 26.51 26.51 - 26.62
Low: 25.57 - 25.71 25.71 - 25.83
Close: 25.78 - 26 26 - 26.19
Company Description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Headline News

Sun, 16 Jun 2024
Anika Therapeutics (ANIK) Gains As Market Dips: What You Should Know - Yahoo New Zealand News

Tue, 11 Jun 2024
Invenomic Capital Management LP Acquires 116,679 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - MarketBeat

Sun, 09 Jun 2024
Anika Therapeutics, Inc. (NASDAQ:ANIK) Holdings Reduced by Trigran Investments Inc. - MarketBeat

Fri, 07 Jun 2024
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Tue, 04 Jun 2024
BNP Paribas Financial Markets Boosts Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World

Thu, 30 May 2024
Anika Therapeutics' (ANIK) Equal Weight Rating Reaffirmed at Stephens - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 15 (M)
Shares Float 11 (M)
Held by Insiders 2.9 (%)
Held by Institutions 91.4 (%)
Shares Short 788 (K)
Shares Short P.Month 811 (K)
Stock Financials
EPS -5.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 14.06
Profit Margin -45.4 %
Operating Margin -23.7 %
Return on Assets (ttm) -1.9 %
Return on Equity (ttm) -31.7 %
Qtrly Rev. Growth 6.9 %
Gross Profit (p.s.) 0
Sales Per Share 11.41
EBITDA (p.s.) 0.26
Qtrly Earnings Growth 0 %
Operating Cash Flow 2 (M)
Levered Free Cash Flow 7 (M)
Stock Valuations
PE Ratio -4.96
PEG Ratio -23.9
Price to Book value 1.84
Price to Sales 2.27
Price to Cash Flow 226.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android